AZ's cleaner efficacy data and lack of thrombotic events in U.S. Phase III could quell vaccine concerns

The U.S. pivotal trial readout for AstraZeneca’s COVID-19 vaccine, if followed by an EUA from FDA, could build global confidence in the safety and efficacy of the product.

AstraZeneca plc (LSE:AZN; NASDAQ:AZN) announced Monday that AZD1222 was 79% protective against symptomatic COVID-19 in the U.S. Phase III trial, which included sites in South America. The pharma also reported no increased risk of thrombosis in those given the vaccine...